Sensing Physics
Accelerated Screening MRI (Longevity Paradigm) C/D grade Plausibility · Instrument plausible/established; the screening paradigm's net benefit (vs overdiagnosis) is unprovenSensing Physics Route ambientInvasiveness non-invasive
The instrument is established; the annual full-body-screening paradigm is not. A public vendor dispute over acquisition quality is carried unresolved on the row.
Origin & lineage
Consumer full-body MRI screening (Prenuvo, Ezra/Function).
Claimed mechanism
Whole-body MRI as an annual longevity-screening paradigm.
Plausibility
Instrument plausible/established; the screening paradigm's net benefit (vs overdiagnosis) is unproven.
Evidence — grade C/D
Instrument established, annual-screening paradigm not. Public vendor dispute over acquisition quality carried unresolved.
Market
Makers: Prenuvo; Function/Ezra.Models: Full-body MRI screening.Price: ~$499–2,500.
Kernel — keep vs set aside Keep — real substrate
MRI is an established, cleared imaging instrument.
Set aside — claim
Annual whole-body screening for longevity has unproven net benefit and real overdiagnosis risk.
Regulatory status by jurisdiction Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA MRI is a cleared instrument; the annual-screening paradigm is not an approved indication. EU — MDR — Russia — China — NMPA — Australia — TGA —
Sources
This is an evidence atlas — a map, not a marketplace and not medical advice. It reports the mechanism, evidence grade, and regulatory status of the modalities it catalogues, including the views and claims of third parties, with sources cited where they exist. Regulatory registration or clearance is a market-access fact, never proof of efficacy. Nothing here is an endorsement, a diagnosis, or a treatment recommendation. Consult a qualified clinician before making any health decision.
Evidence grades reflect the position of scientific consensus on the available evidence and may change. All trademarks belong to their respective owners; cited material remains the property of its authors.
© 2024–2026 devices.longevity.one